REMEGEN (09995) announced its annual results for the period ending December 31, 2025. The group achieved revenue of RMB 3.242 billion, an increase of 89.55% compared to the previous year. Profit attributable to owners of the parent company was RMB 710 million, a turnaround from a loss of RMB 1.468 billion in the same period last year. Earnings per share were RMB 1.29.
Revenue from product sales for the year ended December 31, 2025, was approximately RMB 2.307 billion, a 35.8% increase from RMB 1.699 billion in the prior year. This growth was primarily driven by strong sales of the company's commercial products: Telitacicept (RC18, brand name: Tai Ai®) for autoimmune diseases, and Disitamab Vedotin (RC48, brand name: Ai Di Xi®) for oncology.
As the world's first innovative dual-target biologic for the treatment of systemic lupus erythematosus (SLE), Telitacicept received market approval from China's National Medical Products Administration (NMPA) in March 2021 and commenced sales. In December of the same year, the product for SLE treatment was included in the National Reimbursement Drug List (NRDL), with successful renewals in both 2023 and 2025. In December 2025, the product for the treatment of generalized myasthenia gravis (gMG) was also included in the NRDL. By December 31, 2025, Telitacicept had gained access to over 1,200 hospitals.
Disitamab Vedotin received NMPA approval in June 2021 and began sales in July of that year. At the end of 2021, its indication for HER2-expressing advanced gastric cancer (GC) was included in the updated NRDL. In January 2023, its indication for HER2-expressing urothelial carcinoma (UC) was added to the NRDL. Both indications were successfully renewed in the NRDL at the end of 2025. As of December 31, 2025, Disitamab Vedotin had gained access to over 1,050 hospitals.
Leveraging the expertise and industry connections of its team, along with significantly improved accessibility following the inclusion of its two core products in the NRDL, the company is promoting its products primarily through enhanced marketing strategies targeting physicians. This involves increased direct interaction with key opinion leaders and doctors in relevant therapeutic areas, further expansion into broad markets, and effective differentiation of its product portfolio.
Comments